Known targets — ChEMBL curated mechanism
ADORA1ADORA2AADORA2BADORA3PDE3APDE3BPDE4APDE4BPDE4CPDE4D
The experimentally established mechanism targets of Phenylalanine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 6/20 | 0.67 |
| ▸ | ALPI | P09923 | 1/20 | 0.67 |
| ▸ | PKM | P14618 | 1/20 | 0.67 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.67 |
| ▸ | XIAP | P98170 | 1/20 | 0.67 |
| ▸ | ANPEP | P15144 | 2/20 | 0.59 |
| ▸ | RNPEP | Q9H4A4 | 2/20 | 0.59 |
| ▸ | DNPEP | Q9ULA0 | 2/20 | 0.59 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.58 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.58 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.58 |
| ▸ | LTA4H | P09960 | 2/20 | 0.56 |
| ▸ | SLC15A1 | P46059 | 1/20 | 0.50 |
| ▸ | NOS3 | P29474 | 1/20 | 0.47 |
| ▸ | NOS1 | P29475 | 1/20 | 0.47 |
| ▸ | NOS2 | P35228 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dl-Phenylalanine SCHEMBL23152419 | 1.00 | SLC7A5 (0.67) | SLC7A5ALPIPKMPTGS1XIAP | |
| Phenylalanine SCHEMBL892735 | 1.00 | SLC7A5 (0.67) | SLC7A5ALPIPKMPTGS1XIAP | |
| Dl-Phenylalanine SCHEMBL3401559 | 1.00 | SLC7A5 (0.67) | SLC7A5ALPIPKMPTGS1XIAP | |
| Phenylalanine SCHEMBL7542588 | 0.97 | SLC7A5 (0.63) | SLC7A5ALPIPKMPTGS1XIAP | |
| Dl-Phenylalanine SCHEMBL29076351 | 0.94 | SLC7A5 (0.59) | SLC7A5ALPIPKMPTGS1XIAP | |
| Phenylalanine SCHEMBL2634732 | 0.94 | SLC7A5 (0.76) | SLC7A5ALPIPKMPTGS1XIAP | |
| Phenylalanine SCHEMBL10945389 | 0.94 | SLC7A5 (0.76) | SLC7A5ALPIPKMPTGS1XIAP | |
| Dl-Phenylalanine SCHEMBL208388 | 0.94 | SLC7A5 (0.76) | SLC7A5ALPIPKMPTGS1XIAP | |
| D-Phenylalanine SCHEMBL10775923 | 0.94 | SLC7A5 (0.76) | SLC7A5ALPIPKMPTGS1XIAP | |
| Dl-Phenylalanine SCHEMBL31087886 | 0.94 | SLC7A5 (0.76) | SLC7A5ALPIPKMPTGS1XIAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11793853-B2 | Retinylamine derivitives for treatment of ocular disorders | CASE WESTERN RESERVE UNIVERSITY (US) | 2023-10-24 | — | — | US | claimed |
| CN-113912524-A | Polypeptide compound containing sulfamide and synthesis method thereof | 华东师范大学 | 2022-01-11 | — | — | CN | claimed |
| US-20200121754-A1 | RETINYLAMINE DERIVITIVES FOR TREATMENT OF OCULAR DISORDERS | CASE WESTERN UNIVERSITY | 2020-04-23 | — | — | US | claimed |
| US-10471118-B2 | Retinylamine derivitives for treatment of ocular disorders | CASE WESTERN RESERVE UNIVERSITY (US) | 2019-11-12 | — | — | US | claimed |
| WO-2008076771-A2 | COATINGS OF ACRYLAMIDE-BASED COPOLYMERS | ABBOTT CARDIOVASCULAR SYSTEMS INC. (US) | 2008-06-26 | — | — | WO | claimed |
| CN-117706083-A | Chemiluminescent immunoassay kit, preparation method and detection method thereof | 深圳市卓润生物科技有限公司 | 2024-03-15 | — | — | CN | disclosed |
| CN-111936550-B | Decomposable polyethylene glycol derivative | 日油株式会社 | 2023-11-28 | — | — | CN | disclosed |
| US-11793853-B2 | Retinylamine derivitives for treatment of ocular disorders | CASE WESTERN RESERVE UNIVERSITY (US) | 2023-10-24 | — | — | US | disclosed |
| CN-113912524-A | Polypeptide compound containing sulfamide and synthesis method thereof | 华东师范大学 | 2022-01-11 | — | — | CN | disclosed |
| US-20210147624-A1 | DEGRADABLE POLYETHYLENE GLYCOL DERIVATIVE | NOF CORPORATION (JP) | 2021-05-20 | — | — | US | disclosed |
| EP-3778705-A1 | DEGRADABLE POLYETHYLENE GLYCOL DERIVATIVE | NOF Corporation (JP) | 2021-02-17 | — | — | EP | disclosed |
| EP-3778628-A1 | DEGRADABLE POLYETHYLENE GLYCOL CONJUGATE | NOF Corporation (JP) | 2021-02-17 | — | — | EP | disclosed |
| US-5677195-A | FORMING OLIGONUCLEOTIDES OR PEPTIDES BY FORMING FLOW CHANNELS IN SUBSTRATE SURFACE, EACH OF FLOW CHANNELS COMPRISING WALLS WHICH FORM FLUID-TIGHT SEALS WITH SURFACE AND A FLOW INTAKE AND OUTLET, FLOWING NUCLEIC ACIDS THROUGH CHANNELS TO BIND | AFFYMAX TECHNOLOGIES N.V. (NL) | 1997-10-14 | — | — | US | disclosed |
| WO-1997012897-A1 | METHOD TO IDENTIFY A SURFACE-BOUND MOLECULE | THE PENN STATE RESEARCH FOUNDATION (US) | 1997-04-10 | — | — | WO | disclosed |
| EP-0751950-A1 | METHOD FOR IDENTIFYING MEMBERS OF COMBINATORIAL LIBRARIES | THE PENN STATE RESEARCH FOUNDATION (US) | 1997-01-08 | — | — | EP | disclosed |
| WO-1995025737-A1 | METHOD FOR IDENTIFYING MEMBERS OF COMBINATORIAL LIBRARIES | THE PENN STATE RESEARCH FOUNDATION (US) | 1995-09-28 | — | — | WO | disclosed |
| US-5384261-A | Channel blocking on rotating stage, treatment with light | AFFYMAX TECHNOLOGIES N.V. (AN) | 1995-01-24 | — | — | US | disclosed |
| EP-0624059-A4 | COMBINATORIAL STRATEGIES FOR POLYMER SYNTHESIS. | — | 1994-12-21 | — | — | EP | disclosed |
| EP-0624059-A1 | COMBINATORIAL STRATEGIES FOR POLYMER SYNTHESIS | AFFYMAX TECHNOLOGIES N.V. (AN) | 1994-11-17 | — | — | EP | disclosed |
| WO-1993009668-A1 | COMBINATORIAL STRATEGIES FOR POLYMER SYNTHESIS | AFFYMAX TECHNOLOGY N.V. (AN) | 1993-05-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200121754-A1 | RETINYLAMINE DERIVITIVES FOR TREATMENT OF OCULAR DISORDERS | LRAT, RBP1, RBP4 | SLC7A5 761/4885ALPI 3973/4885PKM 3479/4885 |
| US-10471118-B2 | Retinylamine derivitives for treatment of ocular disorders | RBP1, LRAT, RBP4 | SLC7A5 737/4885ALPI 3354/4885PKM 3128/4885 |
| US-11793853-B2 | Retinylamine derivitives for treatment of ocular disorders | LRAT, RBP1, RBP4 | SLC7A5 761/4885ALPI 3973/4885PKM 3479/4885 |
| US-20210147624-A1 | DEGRADABLE POLYETHYLENE GLYCOL DERIVATIVE | LNPEP, CD68, VMP1 | SLC7A5 208/4885ALPI 2925/4885PKM 1662/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.